Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income (loss) attributable to MariMed Inc.	$ 122,309	$ (210,189)
Net income (loss) attributable to non-controlling interests	177,852	182,768
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	263,624	166,108
Equity compensation	284,640	5,154
Loss on debt conversions	482,133
Unrealized trading losses, net		(268)
Changes in operating assets and liabilities:
Accounts receivable, net	(793,081)	(302,237)
Deferred rents receivable	(71,887)
Due from third parties	(467,583)	(355,130)
Due from related parties	52,727	77,594
Other current assets	(66,422)	(180,751)
Other assets	(169,990)	(268)
Accounts payable and accrued expenses	3,095,297	256,035
Due to related parties	(53,342)	108,477
Deferred revenue	(226,950)
Other liabilities	500	(20,000)
Net cash provided by (used in) operating activities	2,629,827	(277,861)
Cash flows from investing activities:
Purchases of fixed assets	(11,502,688)	(3,346,355)
Proceeds from issuance of notes receivable	29,625	16,587
Net cash used in investing activities	(11,473,063)	(3,329,768)
Cash flows from financing activities:
Proceeds from subscribed preferred stock	200,000
Issuance of common stock	5,150,000	206,157
Issuance of promissory notes	3,650,000	2,867,592
Proceeds from (paydown of) mortgage payable	(80,622)	892,810
Exercise of stock options	7,500
Distributions		(301,749)
Net cash provided by financing activities	8,926,878	3,664,810
Net change to cash and cash equivalents	83,642	57,181
Cash and cash equivalents at beginning of period	569,356	160,859
Cash and cash equivalents at end of period	652,998	218,040
Supplemental disclosure of cash flow information:
Cash paid for interest	418,738	158,489
Cash paid for taxes	8,138
Non-cash activities:
Equity issued to convert debt	$ 2,050,000